Omeros Corporation's SEC filings document the regulatory record of a commercial-stage biotechnology company focused on protein and small-molecule therapeutics, including YARTEMLEA, OMS1029 and programs in complement-mediated diseases, cancers, and addictive or compulsive disorders. Form 8-K reports cover operating and financial results, material-event disclosures, clinical and regulatory updates, material agreements, and capital-structure matters.
Proxy materials describe annual shareholder meeting mechanics, director elections, executive-compensation votes, board governance and related shareholder voting matters. The filing record also includes formal disclosure of the FDA approval of YARTEMLEA for TA-TMA and financial-condition information tied to Omeros' commercialization and development-stage pipeline.
OMEROS CORP (OMER) received a Rule 144 notice from director Arnold C. Hanish covering a planned sale of 5,000 shares of Omeros common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC, following an exercise of options under a registered plan, with an indicated value of $94,132.50 and a proposed sale date of 08/26/2026 on NASDAQ.
OMEROS CORP (OMER) reports that its VP, Finance & CAO, David J. Borges, exercised employee stock options and sold the resulting common shares. On August 21 and 24, 2026, he exercised options to acquire a total of 10,906 shares of common stock at exercise prices of $2.94 and $3.93 per share, then sold 10,906 shares of common stock in open-market transactions at prices of $18.95 and $19.10 per share.
The sales were made pursuant to a previously established Rule 10b5-1 trading plan adopted on February 10, 2026. The exercised options relate to grants that vest over 48 equal monthly installments starting April 1, 2022 and April 1, 2023, with expiration dates in 2032 and 2033. All transactions are reported as direct ownership; post-transaction share holdings are not specified in this filing.
OMEROS CORP (OMER) director Thomas J. Cable reported an option exercise-and-sale transaction. He exercised 15,000 Stock Options (Rights to Buy) for 15,000 shares of Common Stock at exercise prices of $2.00 and $3.93 per share, then sold 15,000 shares at a weighted average price of $18.4515 per share in multiple trades ranging from $18.23 to $18.72.
OMEROS CORP (OMER) received a notice that officer David Joseph Borges intends to sell company common stock under Rule 144. The filing covers up to 10,906 shares of common stock, to be obtained by the exercise of stock options and sold for cash, with sales referenced as occurring around 08/21/2026 through a brokerage account at Morgan Stanley Smith Barney LLC on NASDAQ.
The notice also lists a prior sale under a Rule 10b5-1 trading plan in the past three months, where 5,000 shares of common stock were sold for $84,750.00 on 08/13/2026. The remarks state that the securities to be sold were and will be received upon option exercise over the next three months, with the dates of acquisition and payment matching the exercise or sale dates.
OMEROS CORP (symbol OMER) has a notice from director Thomas Cable to sell common stock under Rule 144. The filing lists up to 15,000 shares of common stock to be sold through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $276,772.50. The shares are to come from the exercise of options under a registered plan, in two tranches of 7,500 shares each on 08/20/2026, with cash exercise. The notice also reports that Cable sold 7,500 shares of common stock for $86,806.20 on 05/22/2026 during the prior three months.
OMEROS CORP (OMER) reported that director Joseph L. Schocken received a grant of 30,000 stock options to purchase common stock. The options have an exercise price of $13.71 per share and expire on August 11, 2036. They vest in equal annual installments over three years beginning on the first anniversary of the grant date, and following this grant he holds 30,000 derivative securities directly.
OMEROS CORP (OMER) director Joseph L. Schocken filed an initial Form 3 reporting his beneficial ownership of the company’s common stock. He reports 380,472 shares held directly, and additional indirect holdings of 145,100 shares through Tranceka, LLC and 2,510 shares through Tranceka Holdings, LLC. Tranceka, LLC is wholly owned by Schocken and his spouse and is the sole owner of Tranceka Holdings, LLC.
Omeros Corp executive David J. Borges reported an option exercise and same-day sale of common stock. On August 13, 2026, he exercised 5,000 stock options with an exercise price of $3.93 per share, acquiring 5,000 common shares, and then sold 5,000 common shares at $16.95 per share in an open-market transaction. The filing states that the sale was made under a previously established Rule 10b5-1 trading plan, and that following the option exercise, 15,000 options of this grant remained outstanding, continuing to vest in equal monthly installments from a vesting commencement date of April 1, 2022.
Omeros Corporation expanded its Board of Directors to nine members and appointed Joseph Schocken as a director effective August 12, 2026. His initial term runs until the Company’s 2027 annual meeting of shareholders or earlier resignation or removal.
Schocken, 79, is a private investor and founder and president of Tranceka Capital, LLC, with a long history in investment banking and public-company leadership. He was also a driving participant in national economic policy discussions and the JOBS Act and currently serves as chairman of Taqtile, Inc.
Under Omeros’ non-employee director compensation policy, Schocken received a stock option to purchase 30,000 shares of common stock on his appointment date and will be covered by the Company’s standard director indemnification agreement. He joins the Board’s Audit Committee, and the Company states he has no disclosable material interests in related-party transactions.